报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 61.41% | -1.74% | -0.36% | 48/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 61.63% | -2.89% | -2.44% | 48/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 63.17% | -2.84% | 4.24% | 42/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 60.6% | 4.11% | -3.02% | 52/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 62.49% | 8.57% | -1.53% | 47/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 63.46% | 10.32% | -2.39% | 50/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 65.02% | 2.12% | 11.69% | 41/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 58.21% | 16.14% | 1.13% | 63/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 57.56% | 12.84% | 0.06% | 64/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 57.53% | 14.01% | -9.64% | 67/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 63.67% | 55.12% | 27.02% | 48/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 50.12% | -8.58% | -1.75% | 86/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 51.01% | 27.34% | 1.1% | 72/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 50.46% | -9.68% | -7.97% | 79/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
2020-12-31 | 54.82% | 28.93% | -1.86% | 72/160 | -143.08% | 艾力斯 | 99.4% | 行业排名> |
2020-06-30 | 55.86% | 32.43% | 31.38% | 62/160 | 54.32% | 首药控股 | 99.94% | 行业排名> |
2019-12-31 | 42.52% | -5.01% | 6.14% | 94/160 | -1204.25% | 泽璟制药 | 99.96% | 行业排名> |
2019-09-30 | 40.06% | 2% | -5.04% | 79/160 | 55.47% | 微芯生物 | 95.14% | 行业排名> |
2019-06-30 | 42.19% | 2% | 2.78% | 79/160 | 55.36% | 多瑞医药 | 95.59% | 行业排名> |
2019-03-31 | 41.04% | 2% | -8.31% | 74/160 | 51.37% | 微芯生物 | 95.81% | 行业排名> |
2018-12-31 | 44.76% | 2% | 2% | 81/160 | -205.91% | 微芯生物 | 96.09% | 行业排名> |